BusinessAxsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business UpdateBy Nasdaq OMXMay 8, 2018, 11:01 AM UTC
BusinessAxsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric AssociationBy Nasdaq OMXMay 3, 2018, 11:02 AM UTC
BusinessAxsome Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018By Nasdaq OMXMay 1, 2018, 11:01 AM UTC
BusinessAxsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant DepressionBy Nasdaq OMXApr 26, 2018, 11:01 AM UTC
BusinessAxsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine DependenceBy Nasdaq OMXApr 24, 2018, 11:01 AM UTC
BusinessAxsome Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of AXS-05 in Smoking CessationBy Nasdaq OMXApr 23, 2018, 11:00 AM UTC
BusinessAxsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial OfficerBy Nasdaq OMXApr 19, 2018, 11:00 AM UTC
BusinessAxsome Therapeutics to Participate in the Leerink Partners’ 2018 CNS DayBy Nasdaq OMXApr 11, 2018, 11:00 AM UTC
